Medtronic Set to Soar in 2026 with Strong PFA Franchise and Spinning Off Diabetes Care Unit

Medtronic's recent quarterly update shows strong revenue growth of 6.6% YoY to $9 billion and adjusted EPS up 8% to $1.36. The company's Pulse Field Ablation franchise, which treats atrial fibrillation, drove growth. Medtronic is gaining market share in this niche and expects continued traction. The spin-off of its diabetes care unit, weak margins, and stiff competition in the space are expected to be beneficial. The company is also close to earning clearance for its Hugo robotic-assisted surgery system.